← Signals · Healthcare · TSXV
$TLT
Theralase Technologies Inc.
Signal as of October 14, 2026  ·  90-day rolling window  ·  Medical Equipment & Supplies
Confluence Score
41
out of 100  ·  Full breakdown →
Score delayed 7 days on Free  ·  See today's score — Analyst →
Signals scoring 40–59 have historically hit 41% of the time (avg +7.1% over 90 days, 4424 backtested signals). Methodology →
🔒 Risk monitoring — insider-selling & reversal warnings (Analyst)
1 open-market buy  ·  1 unique buyer  ·  $8K total Lobbying: 0 regs  ·  Contracts: 0 wins
📅 Buying into earnings — Nov 10 (20d)
Confluence Score
41
Unlock breakdown →
Insider Activity (90d)
1
1 buyer  ·  $8K  ·  open-market only
Current Price
$0.19
CAD  ·  5-min cache
Market Cap
$49M
CAD  ·  TMX
Lobbying & Contracts
None
0 regs  ·  0 contracts
Healthcare on Form55: 54% hit rate · -3.8% alpha vs XIU.TO · 28 closed signals Track Record →
★
Signal Analyst
The Confluence Score and insider trade feed above are free. Signal Analyst adds the full component breakdown, lobbying registrations, and contract wins — plus alerts when this company's signal moves, so you don't have to keep checking back.
Monitor — CAD $29/mo
Price Chart
12 months daily  ·  TSXV:TLT
Insider Transactions
90-day window  ·  10 filings
Date Insider Role Nature Dir. Shares Buy Price Return Value
Aug 31, 2026 Bruder, Randall — Comp. Grant Buy 3,360 $0.32 -40.6%  · 51d $1K
Aug 27, 2026 Dumoulin-White, Roger John — Open Market Buy 42,000 $0.18 +5.6%  · 55d $8K
Aug 24, 2026 Hachey, Kristina Maria — Open Market Sell 29,000 $0.24 — $7K
Aug 24, 2026 Hachey, Kristina Maria — Comp. Grant Buy 29,000 $0.32 -40.6%  · 58d $9K
Aug 24, 2026 Dumoulin-White, Roger John — Open Market Sell 31,250 $0.24 — $8K
Aug 24, 2026 Perraton, Matthew Thomas — Open Market Sell 3,360 $0.24 — $806
Aug 24, 2026 Mandel, Arkady — Open Market Sell 14,000 — — —
Aug 24, 2026 Mandel, Arkady — Comp. Grant Buy 14,000 $0.32 -40.6%  · 58d $4K
Aug 24, 2026 Dumoulin-White, Roger John — Open Market Sell 31,250 $0.32 — $10K
Aug 24, 2026 Perraton, Matthew Thomas — Open Market Sell 3,360 $0.32 — $1K
Score uses open-market buys only  ·  1 open-market  ·  3 plan / compensation shown but not scored  ·  Return is unrealized, to today's price; a “· Nd” mark means the 90-day window is still open (N of 90 days) — too early to judge.
Score Breakdown
Signal Analyst  ·  $29/mo
Component Points Max Detail Weight
Conviction (unique buyers)  ✓ FREE PREVIEW 30 30 1 unique buyer (maximum conviction)
Buy/sell ratio 20 14% buys (1B / 6S)
Dollar value 25 $8K
Lobbying activity 15 None
Contract wins 10 None
Insider track record 10 No track record data
Private placements 8 None
Confluence bonus 10 None
Cluster timing (velocity) 10 No coordinated buying cluster detected
Buy/sell reversal pattern 8 1 insider reversed from selling to buying
Total 41 100
Unlock Component Detail — CAD $29/mo
Buying Insiders
Open-market · 90 days · 1 unique buyer
Insider Credibility Hit Rate Avg 90d Return Trades (eval'd) Buy Value (90d) Last Buy
Dumoulin-White, Roger John — — — — $8K Aug 27, 2026
Credibility score: historical hit rate × avg 90d return × sample size. View full insider leaderboard →
Lobbying Registrations
OCL active  ·  none found
No active OCL lobbying registrations in the last 90 days. Analyst plan →
Government Contract Wins
90-day window  ·  none found
No government contract wins in the last 90 days. Analyst plan →
Private Placements
12 months  ·  Signal Analyst  ·  $29/mo
Private placement history, deal size, and lock-up expiry tracking. Analyst plan →
Indigenous Consultation
no records on file

No Indigenous consultation records on file for TLT.

SEDAR+ Filings
official filing registry
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes. Search SEDAR+ →
Short Interest
CIRO  ·  Sep 30, 2026
Shares short
258,665
Net change
+49,065 (+23.4%)
Short interest rose 23% since the prior report.
History
Sep 30: 258,665
Sep 15: 209,600
Aug 31: 139,361
Aug 15: 5,097,704
Jul 31: 61,642
Jul 15: 128,284
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Clinical Trials
ClinicalTrials.gov  ·  2 trials
Phase Status Trial Updated
P2 Recruiting Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolera Nov 2025
P1 Completed Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk No Aug 2018
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and terminations are material catalysts for clinical-stage companies — not investment advice.
Form55 provides data and analysis for informational purposes only. Nothing on this site constitutes investment advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.